Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 195,662,496
  • Shares Outstanding, K 2,696,190
  • Annual Sales, $ 40,122 M
  • Annual Income, $ 2,394 M
  • 36-Month Beta 0.81
  • Price/Sales 4.86
  • Price/Cash Flow 12.66
  • Price/Book 5.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 1.16
  • Number of Estimates 5
  • High Estimate 1.17
  • Low Estimate 1.13
  • Prior Year 1.11
  • Growth Rate Est. (year over year) +4.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
67.82 +6.16%
on 10/11/18
73.49 -2.03%
on 10/22/18
+0.90 (+1.27%)
since 09/21/18
3-Month
62.38 +15.42%
on 07/27/18
73.49 -2.03%
on 10/22/18
+9.31 (+14.85%)
since 07/23/18
52-Week
52.83 +36.29%
on 04/03/18
73.49 -2.03%
on 10/22/18
+8.60 (+13.56%)
since 10/23/17

Most Recent Stories

More News
Angelica Extract Category - Global Procurement Market Report (2018-2022) Featuring Merck, Ultra International, Bio-Botanica, NOW Health Group, Mighty International, and Young Living Essential Oils - ResearchAndMarkets.com

The "Global Angelica extract category - Procurement Market Intelligence Report" report has been added to ResearchAndMarkets.com's offering.

MRK : 72.32 (-0.34%)
MKKGY : 21.4100 (-0.86%)
High BP/Hypertension Drugs and Device Market 2018 – Industry Analysis, Size, Share, Strategies and Forecast to 2023

VRX.TO : 30.80 (-3.33%)
BAYRY : 22.0000 (-2.16%)
CNAT : 4.50 (-5.66%)
RETA : 57.85 (-1.67%)
MRK : 72.32 (-0.34%)
LLY : 110.49 (-1.37%)
NVS : 86.69 (-0.47%)
TKPYY : 20.2200 (-0.74%)
PFE : 44.12 (-0.56%)
OPHLF : 28.8300 (+1.55%)
BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?

We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.

JNJ : 138.56 (-0.09%)
MRK : 72.32 (-0.34%)
NVS : 86.69 (-0.47%)
RHHBY : 30.7100 (+0.38%)
ALKS : 38.86 (-3.24%)
BIIB : 317.48 (+0.61%)
Merck's KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival Compared to Standard of Care, as Monotherapy and in Combination with Chemotherapy, as First-Line Treatment for Patients with Recurrent or Metastatic Head and Neck Cancer

--KEYTRUDA is the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit as First-Line Therapy for Head and Neck Cancer that has Recurred or Metastasized

MRK : 72.32 (-0.34%)
Merck (MRK) to Report Q3 Earnings: What's in the Cards?

Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive third-quarter sales. However, genericization of key drugs and increasing competition are concerns.

MRK : 72.32 (-0.34%)
AMGN : 196.73 (-0.65%)
GSK : 40.19 (-0.77%)
BMY : 50.25 (-1.24%)
The Zacks Analyst Blog Highlights: United Parcel, Merck, BHP, Energy Transfer and Parker-Hannifin

The Zacks Analyst Blog Highlights: United Parcel, Merck, BHP, Energy Transfer and Parker-Hannifin

ETP : 21.47 (-1.38%)
MRK : 72.32 (-0.34%)
PH : 152.73 (-3.00%)
UPS : 114.21 (-1.24%)
BHP : 45.86 (-2.61%)
Merck (MRK) Gains As Market Dips: What You Should Know

Merck (MRK) closed the most recent trading day at $72.35, moving +0.19% from the previous trading session.

MRK : 72.32 (-0.34%)
Agios Rides on Tibsovo Approval Amid Reliance on Celgene

Agios (AGIO) aims at commercializing its newly approved leukemia drug Tibsovo, which has great potential in the AML market. Heavy reliance on Celgene for royalties and collaboration revenues is a woe.

AGIO : 62.81 (-6.09%)
CELG : 79.47 (-1.41%)
AZN : 39.17 (-0.81%)
MRK : 72.32 (-0.34%)
Top Stock Reports for UPS, Merck & BHP Billiton

Top Stock Reports for UPS, Merck & BHP Billiton

ETP : 21.47 (-1.38%)
PCAR : 56.84 (-6.05%)
MRK : 72.32 (-0.34%)
PH : 152.73 (-3.00%)
UPS : 114.21 (-1.24%)
BHP : 45.86 (-2.61%)
Alkermes Boasts Strong Portfolio and Impressive Pipeline

Alkermes (ALKS) has a strong product portfolio, including a number of pipeline candidates with significant potential.

MRK : 72.32 (-0.34%)
LLY : 110.49 (-1.37%)
ALKS : 38.86 (-3.24%)
BIIB : 317.48 (+0.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade MRK with:

Business Summary

Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies...

See More

Key Turning Points

2nd Resistance Point 74.28
1st Resistance Point 73.42
Last Price 72.32
1st Support Level 71.78
2nd Support Level 71.00

See More

52-Week High 73.49
Last Price 72.32
Fibonacci 61.8% 65.60
Fibonacci 50% 63.16
Fibonacci 38.2% 60.72
52-Week Low 52.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar